Compounded Semaglutide: Complete Cost and Safety Guide

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Compounded semaglutide is a preparation made by a licensed pharmacy pursuant to a prescription for an individual patient. It is not an FDA-approved finished product, the agency does not review compounded preparations for safety, effectiveness or quality before they are marketed, and it is not a generic version of Wegovy or Ozempic — neither brand has an approved generic. That is the starting point for any honest cost and safety discussion, because the price advantage people are drawn to and the regulatory difference they are accepting are two sides of the same fact.

What Compounding Is, and What It Is Not

Compounding is a long-standing part of pharmacy practice. Section 503A of the Federal Food, Drug, and Cosmetic Act governs state-licensed pharmacies and physicians preparing medications for identified individual patients. PlexusDx works exclusively with licensed 503A compounding pharmacies.

What compounding is not is an alternative approval pathway. An approved product carries an FDA-reviewed label, a national drug code, and a manufacturer answerable for every lot. A compounded preparation carries a pharmacy, a prescription and a patient name. Both can be legitimate; they are not equivalent, and any marketing that blurs them should raise your guard.

The 503A and 503B distinction is also worth knowing, because the terms appear constantly and are frequently misused. A 503A pharmacy prepares medications for identified individual patients pursuant to prescriptions. A 503B outsourcing facility registers with the FDA and can produce larger batches without patient-specific prescriptions, under different oversight. PlexusDx uses 503A pharmacies only.

There is also a third category that is neither: peptide material sold online without a prescriber or a pharmacy, frequently under research-use labeling. That is not compounding in any regulatory sense, and it is where most of the documented harm has occurred.

How the Landscape Changed in 2025 and 2026

For roughly two years, compounded GLP-1s were widely available because the approved products were in shortage. That ended. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, then set deadlines after which compounders could no longer produce preparations that are essentially copies of the approved drugs.

The specific dates were February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities on tirzepatide, and April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities on semaglutide.

The phrase "essentially a copy" is the operative one. Compounding did not become unlawful; producing duplicates of commercially available approved products under a shortage rationale did. In February 2026 the FDA went further, announcing its intent to restrict GLP-1 active pharmaceutical ingredients intended for non-FDA-approved compounded drugs and to act against marketing that presents compounded products as generic versions of, or the same as, approved drugs.

What the FDA Has Flagged on Safety

The agency's safety communication on unapproved GLP-1 drugs is the most useful single document here, and it names four distinct problems.

Dosing and measurement errors come first: the FDA describes adverse event reports involving mistakes in measurement and administration, some requiring hospitalization, and prescribing of doses beyond what the approved label supports — higher single doses, more frequent administration, faster titration. As of May 31, 2026 the agency had documented 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide, while noting that federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events, so those figures understate the real total.

The others are salt forms, sourcing and marketing. The FDA has flagged compounders using semaglutide sodium and semaglutide acetate, which are different active ingredients from the approved product, and states it lacks information on whether those salts share the same chemical and pharmacologic properties. It has also acted against companies selling unapproved GLP-1 products labeled "for research purposes" or "not for human consumption" while shipping them to consumers with dosing instructions.

The Questions That Separate a Pharmacy From a Seller

Four questions do most of the work. Who is the prescribing clinician, and are they licensed in your state? Which pharmacy is dispensing, and what is its licence number? Is the active ingredient semaglutide base rather than a salt form? And what testing does the pharmacy perform on each lot?

A legitimate operation answers all four without hesitation. A gray-market seller deflects at least one, usually the first. If a website will ship without a prescription at all, no further diligence is necessary.

Two more signals are useful. Ask whether a licensed clinician reviews your medical history before anything is dispensed, and whether there is a named person to contact if you have a reaction. Services that cannot answer those questions are selling a product, not delivering care, and the difference shows up precisely when something goes wrong.

What It Costs Through PlexusDx

PlexusDx publishes flat pricing with no membership fee and no insurance requirement. Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan, and Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. The Precision Peptide Genetic Test is $298.

Flat pricing is worth understanding as a structure, not just a number. It includes the clinical intake and the medication, and it does not change with a deductible reset or a formulary revision mid-year. That predictability is much of the appeal.

Compare on total cost rather than headline rate. A monthly figure that excludes the clinical visit, or that resets after an introductory period, is not comparable to one that does not. Ask what is included, what happens at renewal, and what a change in treatment plan does to the price before committing to a multi-month term.

What Insurance Usually Does

Generally, nothing. Because compounded preparations are not approved products, they typically fall outside pharmacy benefit design, which means paying cash and, importantly, means that spending does not count toward a deductible or out-of-pocket maximum.

Before defaulting to cash, it is worth confirming what your plan actually does with the approved brands for your specific diagnosis. Denials for weight-management indications are frequently documentation problems rather than clinical judgments, and an appeal with the right records succeeds more often than people expect.

Weighing the Trade-Off Honestly

The case for a compounded preparation is access and predictable cost through a licensed pharmacy with a real prescriber attached. The case against is that the FDA has not reviewed that specific preparation for safety, effectiveness or quality, and that the evidence base you have read about was generated with the approved products.

Both of those statements are true simultaneously. The right decision depends on your clinical situation, your coverage, and your own tolerance for that difference — which is exactly the kind of judgment that belongs in a conversation with a prescriber rather than in a comparison chart.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide the same as Wegovy or Ozempic?

No. Compounded semaglutide is not an FDA-approved finished product, and the agency does not review compounded preparations for safety, effectiveness or quality before they are marketed. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. It is not a generic version of either brand, because neither Wegovy nor Ozempic has an approved generic equivalent. The FDA has also acted against marketing that presents compounded products as equivalent.

Why did compounded GLP-1 availability change in 2025?

Because the shortages ended. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, then set deadlines after which compounders could no longer produce preparations that are essentially copies of the approved drugs: February 18 and March 19, 2025 for tirzepatide, and April 22 and May 22, 2025 for semaglutide, for 503A pharmacies and 503B outsourcing facilities respectively.

What safety concerns has the FDA raised about compounded semaglutide?

Four main ones. Dosing and measurement errors, with adverse event reports including hospitalizations and prescribing beyond the approved label. Improper salt forms such as semaglutide sodium and semaglutide acetate, which are different active ingredients. Products sold under research-use labeling but shipped to consumers. And misleading marketing. As of May 31, 2026 the FDA had documented 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide.

How much does compounded semaglutide cost through PlexusDx?

Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan, and Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Pricing is flat, with no membership fee and no insurance requirement.

Does insurance cover compounded semaglutide?

Generally no. Because compounded preparations are not FDA-approved products, they typically sit outside pharmacy benefit design, so they are usually paid for in cash and that spending does not count toward a deductible or out-of-pocket maximum. Before defaulting to cash, confirm what your plan does with the approved brands for your specific diagnosis, since weight-management denials are often documentation problems that a well-supported appeal can resolve.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.